| Svetlana Reilly |
Cardiovascular Medicine |
Cardiovascular medicine |
Screening for hit compounds for the therapeutic purpose of treating cardiac fibrosis |
| Ben Davis |
Chemistry |
Anti-infectives |
Development of novel-mode anti-infectives |
| Gustavo Arruda Bezerra |
Nuffield Department of Medicine |
Anti-infectives |
Screening and characterization of small molecules targeting proteases for antibiotic development |
| Nicole Zitzmann |
Biochemistry |
Anti-infectives |
Towards a novel class of broad-spectrum antivirals |
| Shoumo Bhattacharya |
Wellcome Trust Centre for Human Genetics |
Cardiovascular medicine |
Evasins as chemokine traps for myocarditis |
| Claus Nerlov/Mario Buono |
Weatherall Institute |
Oncology |
Development of inhibitors targeting retrograde signalling in cancer |
| Irina Udalova |
Kennedy Institute |
Inflammation & Immunity |
Developing inhibitor tool compounds to investigate the IRF5 pathway and inflammation |
| Ivan Ahel |
Sir William Dunn School of Pathology |
Anti-infectives |
Development of potent antibacterials against a novel toxin-antitoxin system |
| Kristijan Ramadan |
Oncology |
Oncology |
Development of a first in class protease inhibitor in the field of oncology |
| Ming Lei |
Pharmacology |
Cardiovascular medicine |
Development of a small molecule kinase activator as a drug candidate for the management of heart failure and cardiac hypertrophy |
| Paul Brennan |
Nuffield Department of Medicine |
Oncology |
Inhibition of a Histone Methyl Transferase for the treatment of chemotherapy induced peripheral neuropathy |
| Beth Psaila/Adam Mead |
Weatherall Institute |
Oncology |
Megakaryocytes as novel cellular targets for myelofibrosis, a severe bone marrow disorder |
| David Vaux |
Sir William Dunn School of Pathology |
Neuroscience |
Amyloid oligomerisation inhibitors and microglial stabilisation |
| Cassandra Adams |
Nuffield Department of Medicine |
Musculoskeletal |
Pre-clinical development of a bromodomain inhibitor for the treatment of Dupuytren’s disease |
| Richard Williams |
Kennedy Institute |
Inflammation & Immunity |
Targeting the kynurenin pathway for the treatment of rheumatoid arthritis |
| Kim Midwood |
Kennedy Institute |
Inflammation & Immunity |
Targeting endogenous inflammatory triggers to treat chronic inflammation |
| Kilian Huber |
Nuffield Department of Medicine |
Oncology |
Identification of first-in-class small molecule inhibitors as potential immunooncology therapeutics |
| Yoshi Itoh |
Kennedy Institute |
Musculoskeletal |
Development of stereotactic modifiers selective for the collagenolytic activity of a protease |
| Mark Coles/Chris Buckley |
Kennedy Institute |
Inflammation & Immunity |
Inhibiting tissue damage in rheumatoid arthritis through a first in class therapeutic antibody |
| Alison Simmons |
Weatherall Institute |
Inflammation & Immunity |
Therapeutic targeting of a novel cytokine in Inflammatory Bowel Disease |
